PharmacovigilanceOfficial

EMA publishes PSUSA outcome for nationally authorised split-virion inactivated influenza vaccines, recommending a variation

🇪🇺 EMA · Fri 20 Nov 2026

The EMA has published the single assessment of safety update reports for non-centrally authorised split-virion inactivated influenza vaccines, with the regulatory outcome listed as a variation.

The European Medicines Agency published the outcome of procedure PSUSA/00010298/202603 on 20 November 2026. The procedure covers influenza vaccine (split virion, inactivated) in products that are not centrally authorised, meaning those approved at national level.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: EMA ↗

Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.